SCHEMBL13409587

SCHEMBL13409587

CCc1cccnc1N1CCOCC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.56
CYP2C9 P11712 1/20 0.56
P2RX7 Q99572 1/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
SCN10A Q9Y5Y9 2/20 0.46
SCN2A Q99250 1/20 0.46
POLB P06746 1/20 0.45
LRRK2 Q5S007 1/20 0.44
PIK3CA P42336 2/20 0.44
PKM P14618 1/20 0.44
NMT1 P30419 1/20 0.43
ELANE P08246 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
ALDH1A1 P00352 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22400199 0.85 CYP1A2 (0.53) CYP1A2CYP2C9P2RX7SCN10ASCN2A
SCHEMBL29203362 0.84 CYP1A2 (0.52) CYP1A2CYP2C9P2RX7LMNAMAPK1
SCHEMBL3287525 0.84 CYP1A2 (0.52) CYP1A2CYP2C9P2RX7LMNAMAPK1
SCHEMBL3289804 0.84 CYP1A2 (0.52) CYP1A2CYP2C9P2RX7LMNAMAPK1
SCHEMBL30240829 0.84 CYP1A2 (0.52) CYP1A2CYP2C9P2RX7LMNAMAPK1
SCHEMBL3081290 0.84 CYP1A2 (0.52) CYP1A2CYP2C9P2RX7LMNAMAPK1
SCHEMBL5311868 0.84 CYP1A2 (0.52) CYP1A2CYP2C9P2RX7MAPK1SCN10A
SCHEMBL29526501 0.84 CYP1A2 (0.50) CYP1A2CYP2C9P2RX7MAPK1SCN10A
SCHEMBL4305773 0.83 CYP1A2 (0.55) CYP1A2CYP2C9P2RX7LMNASCN10A
SCHEMBL23344659 0.83 CYP1A2 (0.49) CYP1A2CYP2C9P2RX7MAPK1SCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023131271-A1 PYRROLE FUSED-RING PYRAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 杭州中美华东制药有限公司 2023-07-13 WO disclosed
WO-2021028362-A1 SHP2 INHIBITORS IRBM S.P.A. (IT) 2021-02-18 WO disclosed
EP-3772513-A1 SHP2 INHIBITORS C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) 2021-02-10 EP disclosed
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 US disclosed
US-20140235616-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-21 US disclosed
US-20100093722-A1 HETEROARYL AND PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2010-04-15 US disclosed
US-20080312435-A1 Imine Compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312435-A1 Imine Compound CNR1, CNR2, HRH4 CYP1A2 980/4885CYP2C9 400/4885P2RX7 225/4885
US-20100093722-A1 HETEROARYL AND PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS ADORA2A, ADORA3, ADORA2B CYP1A2 955/4885CYP2C9 2175/4885P2RX7 17/4885
US-20140235616-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CYP11B2, CYP1A2, COQ8A CYP1A2 2/4885CYP2C9 110/4885P2RX7 57/4885
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 CYP1A2 1236/4885CYP2C9 1458/4885P2RX7 1043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.